Responses
Regular Abstracts – Part 2
Novel Single-Agent Immunotherapies
1403-B Sonata’s proprietary intrinsic antigen release technology (iART) drives in situ generation of potent anti-tumor immunity across warm and cold tumor models
Compose a Response to This Article
Other responses
No responses have been published for this article.
